| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/03/2009 | CN100493515C Nano emulsion containing ginsenoside, preparation method and usage |
| 06/02/2009 | US7541463 Lung cancer, gastric cancer, liver cancer, leucocythemia, endometrioma, oophoroma, mammary cancer, colon cancer, prostatic cancer, or pituitary gland cancer; N (N',N'-dimethylaminoethyl)benzo[b]thieno[2,1-c]naphthalimide |
| 06/02/2009 | US7541446 Transcriptional activator fusion proteins which comprises both tetracycline controlled transactivator proteins and reverse tetracycline transactivator proteins |
| 06/02/2009 | US7541437 Breast cancer resistance protein (BCRP) and the DNA which encode it |
| 06/02/2009 | US7541378 tert-butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate; N-benzyl-3-[(4-fluorobenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxamide; treats a disease caused associated with an altered (disregulated) protein kinase activity e.g cancer, cell proliferative disorders, Alzheimer's disease, viral infections |
| 06/02/2009 | US7541375 Azole derivatives and pharmaceutical compositions containing them |
| 06/02/2009 | US7541369 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2009 | US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine |
| 06/02/2009 | US7541354 Bicyclo-pyrazoles |
| 06/02/2009 | US7541334 Hybrid peptides modulate the immune response |
| 06/02/2009 | US7541035 Immunogenic peptides for the treatment of prostate and breast cancer |
| 06/02/2009 | US7541034 Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| 06/02/2009 | US7541031 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα |
| 06/02/2009 | US7541029 Anti-rhesus D monoclonal antibodies |
| 06/02/2009 | US7541027 polyclonal antibodies, monoclonal antibodies, F(ab')2, Fab and single chain Fv; tyrosine at position 1214 in the amino acid sequence of the vascular endothelial growth factor receptor |
| 06/02/2009 | US7541025 Infusion of leukocytes into tumor; side efect reduction; then performing radiation therapy; prevent graft versus host disease |
| 06/02/2009 | US7541018 Treatment process using somatostatin analogues |
| 06/02/2009 | CA2434277C Substituted alkylamine derivatives and methods of use |
| 06/02/2009 | CA2410160C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 06/02/2009 | CA2371728C High dose radionuclide complexes for bone marrow suppression |
| 06/02/2009 | CA2344290C Quinazoline derivatives |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 06/02/2009 | CA2277865C Method of inhibiting cancer growth |
| 06/02/2009 | CA2258539C Ring-fused dihydropyranes, process for the preparation and use thereof |
| 06/02/2009 | CA2226548C Lyophilized hepatocyte growth factor preparations |
| 06/02/2009 | CA2190867C Methods for reduced renal uptake of antibody fragments |
| 06/02/2009 | CA2158475C Composition and method for reducing toxicity of biologically-active factors |
| 05/28/2009 | WO2009067697A1 Therapeutic compounds |
| 05/28/2009 | WO2009067690A2 Methods for safe and effective treatment using oxazaphosphorine drugs |
| 05/28/2009 | WO2009067686A2 Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof |
| 05/28/2009 | WO2009067674A2 Polymorphs of sunitinib base and processes for preparation thereof |
| 05/28/2009 | WO2009067547A1 Polo-like kinase inhibitors |
| 05/28/2009 | WO2009067543A2 Treatment of histone deacetylase mediated disorders |
| 05/28/2009 | WO2009067520A2 Peptides specific for hepatocellular carcinoma cells and applications thereof |
| 05/28/2009 | WO2009067410A1 Small-molecule modulators of trp-p8 activity |
| 05/28/2009 | WO2009067397A2 Treatment for solid tumors |
| 05/28/2009 | WO2009067243A2 Modulation of cd40 expression |
| 05/28/2009 | WO2009067081A1 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis |
| 05/28/2009 | WO2009066775A1 Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
| 05/28/2009 | WO2009066774A1 Selective expression inhibitor for aurora kinase a and aurora kinase b genes |
| 05/28/2009 | WO2009066712A1 Aromatase inhibitor |
| 05/28/2009 | WO2009066655A1 Human antibody capable of inducing apoptosis |
| 05/28/2009 | WO2009066462A1 Method for induction of cytotoxic t-cell, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine each comprising the inducer |
| 05/28/2009 | WO2009066283A2 Calcium-mediated effects of coral and methods of use thereof |
| 05/28/2009 | WO2009066084A1 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| 05/28/2009 | WO2009066062A1 Cancer treatment medicament, use and method of manufacture thereof |
| 05/28/2009 | WO2009065946A2 Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition |
| 05/28/2009 | WO2009065910A2 Acid addition salts of imatinib and formulations comprising the same |
| 05/28/2009 | WO2009065561A2 System for delivery into a xcr1 positive cell and uses thereof |
| 05/28/2009 | WO2009065292A1 Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof |
| 05/28/2009 | WO2009065232A1 Cancer diagnostic and therapeutic methods that target plk4/sak |
| 05/28/2009 | WO2009046880A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009046877A3 Use of a histrelin and leuprolide as therapeutic agents |
| 05/28/2009 | WO2009046822A3 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009043527A3 Therapeutic use of human growth hormone 1-43 |
| 05/28/2009 | WO2009043521A3 Use of urocortin iii and urocortin i as therapeutic agents |
| 05/28/2009 | WO2009043506A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043456A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009040819A3 DOWN-REGULATION OF MORTALIN BY siRNA |
| 05/28/2009 | WO2009040051A3 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009040023A3 Use of galnon as a therapeutic agent |
| 05/28/2009 | WO2009040005A3 Use of the peptide rfmwmr as a therapeutic agent |
| 05/28/2009 | WO2009039983A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009039978A3 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 05/28/2009 | WO2009038757A3 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| 05/28/2009 | WO2009035351A8 Galenic form of drug for treating internal cancerous infections and method for making same |
| 05/28/2009 | WO2009033747A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009033660A3 Use of octreotide as a therapeutic agent |
| 05/28/2009 | WO2009031151A3 Antibodies and methods for diagnosing and treating cancer |
| 05/28/2009 | WO2009026657A8 Flavonoid ppar agonists |
| 05/28/2009 | WO2008156713A3 Anti-cd20 therapeutic compositions and methods |
| 05/28/2009 | WO2008156638A3 Method of treating disorders that would benefit from increased levels of bilirubin in a subject |
| 05/28/2009 | WO2008138327A3 Polymerase inhibitors and the use thereof for the treatment of tumors |
| 05/28/2009 | WO2008125633A3 Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
| 05/28/2009 | WO2008098789A3 Dual acting prodrugs |
| 05/28/2009 | US20090138977 Pancreatic cancer targets and uses thereof |
| 05/28/2009 | US20090137845 Novel 4-Dedimethylaminotetracycline derivatives |
| 05/28/2009 | US20090137805 N-phenyl-2-pyrimidine-amine derivatives |
| 05/28/2009 | US20090137804 Compounds and Compositions as Protein Kinase Inhibitors |
| 05/28/2009 | US20090137782 Recognize aberrant glycosylated form of the EGFR; evident upon aberrant post-translational modification; cancer |
| 05/28/2009 | US20090137683 Anticancer effect enhancer |
| 05/28/2009 | US20090137682 Combination cancer therapy with bis(thiohydrazide) amide compounds |
| 05/28/2009 | US20090137679 ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors |
| 05/28/2009 | US20090137664 Saururus cernuus compounds that inhibit cellular responses to hypoxia |
| 05/28/2009 | US20090137647 Modified Macrophage Migration Inhibitory Factor Inhibitors |
| 05/28/2009 | US20090137640 Potentiator for radiation therapy comprising pyridine derivative as active ingredient |
| 05/28/2009 | US20090137631 Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| 05/28/2009 | US20090137620 Use of gallium(iii) complexes for the treatment of melanomas |
| 05/28/2009 | US20090137619 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| 05/28/2009 | US20090137615 Indazolylamino quinazoline derivatives as antitumour agents |
| 05/28/2009 | US20090137607 6-phenyl-7-(4-{[4-(3-pyridin-2-yl-1,2,4-triazol-5-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2a]-pyrimidine; phosphatidyl inositol 3-kinase inhibitors; anticancer agents; apoptosis |
| 05/28/2009 | US20090137601 L-Phenylalanine Derivatives |
| 05/28/2009 | US20090137597 Novel quinoxalinone derivatives |
| 05/28/2009 | US20090137596 G-protein inhibitor |
| 05/28/2009 | US20090137592 Morpholines as selective inhibitors of cytochrome p450 2a13 |
| 05/28/2009 | US20090137588 Heteroaryl compounds and uses thereof |
| 05/28/2009 | US20090137585 N-acylsulfonamide apoptosis promoters |
| 05/28/2009 | US20090137581 Heterocyclic compounds and their uses |
| 05/28/2009 | US20090137580 Fused Heterocyclic Derivatives and Use Thereof |
| 05/28/2009 | US20090137572 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders |